Skip to main content
DEINOVE logo

DEINOVE — Investor Relations & Filings

Ticker · ALDEI ISIN · FR0010879056 LEI · 969500BEJSRFER0F2K08 PA Professional, scientific and technical activities
Open in API
Filings indexed 300 across all filing types
Latest filing 2022-04-07 Regulatory Filings
Country FR France
Listing PA ALDEI

About DEINOVE

https://www.deinove.com

DEINOVE is a biotechnology company that discovers, develops, and produces high-value compounds derived from rare bacteria and microorganisms, often referred to as 'microbial dark matter'. Leveraging a proprietary technology platform, the company harnesses the metabolic potential of extremophilic bacteria, such as Deinococcus, to create innovative solutions. Its primary applications are focused on developing novel bio-based active ingredients, including carotenoids, for the cosmetics sector, and discovering new antibiotics to address the global challenge of antimicrobial resistance.

Recent filings

Filing Released Lang Actions
The second part of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections to be extended to Canada
Regulatory Filings Classification · 1% confidence The document is a press release dated April 7, 2022, announcing the extension of a Phase II clinical trial for the drug DNV3837 into Canada. It details clinical trial progress, expert involvement, and background information on the target infection (*Clostridioides difficile*). This type of announcement, detailing operational updates, clinical progress, and strategic business developments, is characteristic of an Earnings Release (ER) if it were focused on financial results, or more generally, a Regulatory Filing (RNS) if it doesn't fit a more specific operational category. Since it is not a full financial report (10-K, IR), a management discussion (MDA), or a specific financing event (CAP), and it is a formal announcement of a business/clinical update, it fits best under the general Regulatory Filings category (RNS) or potentially an Earnings Release (ER) if such updates are bundled there. Given the focus is purely on clinical trial expansion and not financial performance highlights, RNS is the most appropriate general regulatory announcement category, although it shares characteristics with an Investor Presentation (IP) or Management Report (MDA) in content style. However, as a formal press release announcing a material operational event, RNS serves as the best fit among the provided options for non-financial, non-meeting related announcements.
2022-04-07 English
La 2ème partie de l’essai clinique de Phase II de DNV3837 dans les infections à Clostridioïdes difficile sera étendue au Canada
Regulatory Filings Classification · 1% confidence The document is a press release from DEINOVE announcing the extension of its Phase II clinical trial for DNV3837 into Canada. It details the trial's progression, the involvement of a new medical lead, and provides background information on the disease (*Clostridioides difficile* infections) and the drug candidate (DNV3837). This type of announcement, detailing clinical trial updates, drug development progress, and strategic business moves, is characteristic of an Investor Presentation (IP) or a general press release related to R&D. Since it is a detailed update on clinical progress and strategy, 'Investor Presentation' (IP) is the most fitting category among the specific options, as it functions as a detailed update for investors, even if formatted as a press release. It is not a formal regulatory filing like 10-K or IR, nor is it a short announcement of a report (RPA/RNS).
2022-04-07 French
Michael MOUREZ rejoint l’équipe de DEINOVE en tant que Directeur de l’Innovation
Board/Management Information Classification · 1% confidence The document is a press release dated March 17, 2022, announcing the appointment of Dr. Michael MOUREZ as the Director of Innovation. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The document is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). Therefore, the appropriate classification is MANG.
2022-03-17 French
Michael MOUREZ joins the DEINOVE team as Chief Innovation Officer
Board/Management Information Classification · 1% confidence The document announces the appointment of a new executive, Michael MOUREZ, as Chief Innovation Officer. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information (MANG). The text is a press release format, not a comprehensive financial report (like 10-K or IR) or a transcript.
2022-03-17 English
Grâce au programme AGIR, DEINOVE est devenue une biotech industrielle d’exception dans la lutte contre l’antibiorésistance
Regulatory Filings Classification · 1% confidence The document announces the closure of the 'AGIR' program, detailing the technological and industrial expertise developed in collaboration with the Institut Charles Viollette to combat antibiotic resistance. It describes the platform built, the scientific achievements (new strains, active extracts, dereplication), and includes quotes from management (Scientific Director, Deputy Director, CEO). This content is characteristic of a detailed update on a significant research/development project, often released to inform investors about progress and capabilities. It is not a formal regulatory filing like a 10-K, a short earnings release (ER), or a simple dividend notice. It functions as a detailed progress report or a scientific/industrial update. Given the options, it most closely resembles an Investor Presentation (IP) in terms of content depth and audience focus, or potentially a specialized Management Report (MDA) focusing on R&D milestones, but 'Investor Presentation' fits the narrative style of highlighting achievements and future potential to the investment community well. Since it is a detailed narrative update on strategic progress rather than a formal financial statement or a standard presentation deck, MDA is a strong candidate, but IP often covers these strategic R&D milestones. However, since it is a press release format announcing the *completion* of a structured program, it is often categorized as a general update. Given the focus on scientific and industrial capabilities built through a government-backed program, it is a strategic update. I will classify it as an Investor Presentation (IP) as it serves to present the company's enhanced capabilities to investors.
2022-03-02 French
Thanks to the AGIR program, DEINOVE has become a unique French industrial biotech in the fight against antibiotic resistance
Regulatory Filings Classification · 1% confidence The document is a press release dated March 2nd, 2022, announcing the conclusion of the AGIR program and highlighting the resulting technological and industrial achievements of DEINOVE in fighting antibiotic resistance. It details scientific progress, quotes management, and provides company background. This format—a formal announcement of business/scientific progress rather than a mandated financial filing (like 10-K, IR, or ER)—most closely aligns with a general corporate announcement. Since it is not a specific financial report, management change, dividend notice, or shareholder vote result, the most appropriate general category is Regulatory Filings (RNS), which serves as a broad category for official company announcements that don't fit elsewhere, although it could also be argued as an Investor Presentation (IP) if it were structured as slides, but the text format suggests a press release/news item. Given the nature of announcing a major program conclusion and technological advancement, RNS is the safest general classification for a non-standard announcement.
2022-03-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.